TP53 and ovarian carcinoma: In the present study, the detection of p53 tumor-specific mutations in plasma DNA samples from 100% of patients (6/6) with non-metastatic breast cancer is significantly higher than those observed in colorectal cancer (p = 0.006) and ovarian cancer (p = 0.007).